Skip to main content

Advertisement

Springer Nature Link
Log in

Cancer Risk in Type 2 Diabetes

  • Invited Commentary
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications. 2010;24(5):345–53.

    Article  PubMed  Google Scholar 

  2. Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829–41.

    Article  PubMed  CAS  Google Scholar 

  3. Yang X, So WY, Ma RC, Kong AP, Xu G, Chan JC. Diabetes and cancer: the mechanistic implications of epidemiological analyses from the Hong Kong Diabetes Registry. Diabetes Metab Res Rev. 2012 Feb 8. doi:10.1002/dmrr.2287.

  4. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–85.

    Article  PubMed  Google Scholar 

  5. So WY, Yang X, Ma RC, et al. Risk factors in V-shaped risk associations with all-cause mortality in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Metab Res Rev. 2008;24(3):238–46.

    Article  PubMed  Google Scholar 

  6. Yang X, Ko GT, So WY, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes. 2010;59(5):1254–60.

    Article  PubMed  CAS  Google Scholar 

  7. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–14.

    Article  PubMed  CAS  Google Scholar 

  8. Gerstein HC. Does insulin therapy promote, reduce, or have a neutral effect on cancers? JAMA. 2010;303(5):446–7.

    Article  PubMed  CAS  Google Scholar 

  9. Kong AP, Chan NN, Chan JC. The Role of Adipocytokines and Neurohormonal Dysregulation in Metabolic Syndrome. Curr Diabetes Rev. 2006;2:397–407.

    PubMed  CAS  Google Scholar 

  10. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr. 2001;131(11 Suppl):3109S–20S.

    PubMed  CAS  Google Scholar 

  11. Becker S, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem. 2009;115(2):86–96.

    Article  PubMed  CAS  Google Scholar 

  12. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med. 2010;49(11):1603–16.

    Article  PubMed  CAS  Google Scholar 

  13. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev. 2004;25(6):971–1010.

    Article  PubMed  CAS  Google Scholar 

  14. Cust AE. Physical activity and gynecologic cancer prevention. Recent Cancer Res. 2011;186:159–85.

    Article  Google Scholar 

  15. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A. Is it time to test metformin in breast cancer clinical trials? Canc Epidemiol Biomarkers Prev. 2009;18(3):701–5.

    Article  CAS  Google Scholar 

  16. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer. 2009;9(8):563–75.

    Article  PubMed  CAS  Google Scholar 

  17. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res. 2007;100(3):328–41.

    Article  PubMed  CAS  Google Scholar 

  18. Huang X, Wullschleger S, Shpiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J. 2008;412(2):211–21.

    Article  PubMed  CAS  Google Scholar 

  19. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–5.

    Article  PubMed  Google Scholar 

  20. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29(2):254–8.

    Article  PubMed  Google Scholar 

  21. Yang X, So WY, Ma RC, et al. Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes. 2011;34(2):375–80.

    Article  CAS  Google Scholar 

  22. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3(11):1451–61.

    Article  CAS  Google Scholar 

  23. Yang X, Ma RC, So WY, et al. Low triglyceride and nonuse of statins is associated with cancer in type 2 diabetes mellitus: the Hong Kong Diabetes Registry. Cancer. 2011;117(4):862–71.

    Article  PubMed  CAS  Google Scholar 

  24. Yang X, Zhao H, Sui Y, et al. Additive interaction between the renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes. 2009;58(7):1518–25.

    Article  PubMed  CAS  Google Scholar 

  25. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52(9):1732–44.

    Article  PubMed  CAS  Google Scholar 

  26. Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia. 2009;52(9):1971–3.

    Article  PubMed  CAS  Google Scholar 

  27. Pocock SJ, Smeeth L. Insulin glargine and malignancy: an unwarranted alarm. Lancet. 2009;374(9689):511–3.

    Article  PubMed  Google Scholar 

  28. Yang X, So WY, Ma RC, et al. Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2010;90(3):343–51.

    Article  PubMed  CAS  Google Scholar 

  29. Sliwinska A, Blasiak J, Kasznicki J, Drzewoski J. In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM). Chem Biol Interact. 2008;173(3):159–65.

    Article  PubMed  CAS  Google Scholar 

  30. Sliwinska A, Blasiak J, Drzewoski J. Effect of gliclazide on DNA damage in human peripheral blood lymphocytes and insulinoma mouse cells. Chem Biol Interact. 2006;162(3):259–67.

    Article  PubMed  CAS  Google Scholar 

  31. Sliwinska A, Rogalska A, Szwed M, Kasznicki J, Jozwiak Z, Drzewoski J. Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells. Mol Biol Rep. 2012;39(5):5253–67.

    Google Scholar 

Download references

Disclosure

Conflicts of interest: A.P.S. Kong: has received a sponsorship to attend meetings; received speakers’ honorarium from Merck Serono related to diabetes and cancer; has advisory board membership with Eli Lilly; has been a consultant for Novo Nordisk (did not receive any honoraria) J.C.N. Chan: has been a consultant for Astra Zeneca, Bayer, BMS, GSK, MSD, Lilly, Pfizer, Sanofi, Takeda (donated to CUHK for R/D in diabetes); has received a research grant from Sanofi to study mechanisms of association between cancer and hyperglycemia; and has received payment for lectures including service on speakers bureaus from Astra Zeneca, Bayer, BMS, GSK, MSD, Lilly, Pfizer, Sanofi, Takeda (donated to CUHK for R/D in diabetes).

Author information

Authors and Affiliations

  1. Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, N.T., Hong Kong, SAR, China

    Alice P. S. Kong & Juliana C. N. Chan

  2. Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, SAR, China

    Alice P. S. Kong & Juliana C. N. Chan

  3. Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, SAR, China

    Alice P. S. Kong & Juliana C. N. Chan

Authors
  1. Alice P. S. Kong
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Juliana C. N. Chan
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Alice P. S. Kong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kong, A.P.S., Chan, J.C.N. Cancer Risk in Type 2 Diabetes. Curr Diab Rep 12, 325–328 (2012). https://doi.org/10.1007/s11892-012-0277-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-012-0277-4

Keywords